4-(3,5-bis-benzyloxy-phenyl)-2,4-dioxo-butyric acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(3,5-bis-benzyloxy-phenyl)-2,4-dioxo-butyric acid
• 英文别名: L-708906；4-(3,5-Bis-benzyloxy-phenyl)-2,4-dioxobutanoic acid；4-[3,5-Bis(phenylmethoxy)phenyl]-2,4-dioxobutanoic acid
• 化学式: C₂₄H₂₀O₆
• 分子量: 404.419
• InChiKey: SLRLQBRWUMWEOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  30
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  89.9
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] HIV INTEGRASE INHIBITORS<br/>[FR] INHIBITEURS DE VIH INTEGRASE
  申请人：MERCK & CO., INC.

  公开号：WO1999062520A1

  公开（公告）日：1999-12-09

  (EN) Certain six-membered aromatic and heteroaromatic-dioxo-butyric acid derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.(FR) Cette invention a trait à certains dérivés d'acide dioxo-butyrique à 6 chaînons, aromatique et hétéro-aromatique, agissant en tant qu'inhibiteurs de VIH intégrase et de la réplication du VIH. Ces composés sont utilisés dans le cadre de la prévention et du traitement des infections par le VIH et du sida, que ce soit sous forme de composés, de sels acceptables du point de vue pharmaceutique ou d'ingrédients de composition pharmaceutique, seuls ou associés à d'autres antiviraux, immunorégulateurs, antibiotiques ou vaccins. L'invention concerne également des méthodes de traitement du sida ainsi que des méthodes de prévention et de traitement des infections par VIH.

  某些六元芳香和杂芳二酮丁酸衍生物被描述为HIV整合酶抑制剂和HIV复制抑制剂。这些化合物可用于预防或治疗HIV感染和治疗艾滋病，无论是作为化合物、药学上可接受的盐、药物组成成分，还是与其他抗病毒药物、免疫调节剂、抗生素或疫苗联合使用。还描述了治疗艾滋病的方法以及预防或治疗HIV感染的方法。
• Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
  申请人：Nair Vasu

  公开号：US20070259823A1

  公开（公告）日：2007-11-08

  A new class of diketo acids constructed on nucleobase scaffolds, designed as inhibitors of HIV replication through inhibition of HIV integrase, is described. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as pharmaceutically acceptable salts, with pharmaceutically acceptable carriers, used alone or in combination with antivirals, immunomodulators, antibiotics, vaccines, and other therapeutic agents. Methods of treating AIDS and ARC and methods of treating or preventing infection by HIV are also described.

  描述了一种构建在核碱基支架上的新型二酮酸类化合物，设计用于通过抑制HIV整合酶来抑制HIV复制。这些化合物可作为化合物本身或作为药学上可接受的盐，与药学上可接受的载体单独或与抗病毒药物、免疫调节剂、抗生素、疫苗和其他治疗剂联合使用，用于预防或治疗HIV感染以及治疗艾滋病和ARC。还描述了治疗艾滋病和ARC以及预防或治疗HIV感染的方法。
• EP1082121A4
  申请人：——

  公开号：EP1082121A4

  公开（公告）日：2003-02-05
• HIV INTEGRASE INHIBITORS
  申请人：MERCK & CO., INC.

  公开号：EP1082121A1

  公开（公告）日：2001-03-14
• Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents
  申请人：Leh Herve

  公开号：US20080280849A1

  公开（公告）日：2008-11-13

  The invention relates to a combination comprising a quinoline compound or its sail, according to general formula (I) and at least one HIV infection therapeutic agent selected from the group consisting of entry inhibitors, reverse-transcriptase inhibitors, strand-transfer inhibitors, protease inhibitors, and maturation inhibitors. Said combination has therapeutic synergy in the treatment of an HIV infection compared with the quinoline compound, or HIV infection therapeutic agent alone.